[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemo-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemo-radiotherapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615469","a-study-on-the-effectiveness-of-olive-oil-mouthwash-in-alleviating-chemoradiotherapy-induced-oral-mucositis-in-patients-with-head-and-neck-cancer-100615469",false,"NCT07293013","A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.","Inclusion Criteria:\n\n* A. Aged 20 years or older. B. Diagnosed with a primary cancer located in the head and neck region and preparing to undergo radiotherapy or concurrent chemoradiotherapy (CCRT). For the purposes of this study, CCRT is defined as receiving chemotherapy within one week before or after the first day of radiotherapy.\n\nC. The total prescribed radiotherapy dose is between 6000 and 7200 cGy. D. Conscious and able to communicate in Mandarin or Taiwanese. E. Willing to participate in the study after receiving an explanation, and capable of signing the informed consent form.\n\nExclusion Criteria:\n\nA. Patients diagnosed with recurrent head and neck cancer undergoing a second course of radiotherapy or CCRT.\n\nB. Patients who are allergic or have a history of allergy to any component of the intervention used in this study.\n\nC. Patients who are unable to open their mouth due to skin grafting. D. Patients with known metastasis (M1). E. Patients who have already developed oral mucositis (OM). F. Patients with skin diseases, autoimmune disorders, or those deemed unsuitable for the study by the physician.","ALL","20 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM). It is easy to cause dry mouth and infection, which seriously affects the comfort and quality of life of patients. There are many pharmacological and non-pharmacological mouthwash solutions in clinical practice, the purpose of which is to reduce bacterial accumulation in order to prevent and improve OM. Olive oil has powerful moisturizing, antioxidant and anti-inflammatory properties. There is no research on the use of olive oil in the prevention or treatment of OM.\n\nObjective: The purpose of this study was to evaluate the preventive and therapeutic effects of olive oil as a mouthwash solution on OM caused by radiation therapy or concurrent chemoradiotherapy.\n\nMethods: The research design of this study is a randomized controlled trial. Patients from a radiation oncology clinic of a regional teaching hospital in southern China were invited to participate in the study by intentional sampling. The study will be followed for 12 weeks and will collect data before and after treatment with olive oil mouthwash or standard care. Assessment tools include demographic characteristics, severity of OM (RTOG and OMAS), degree of dry mouth (XQ and Saxon test), pain severity(VAS), Shortened General Comfort Questionnaire (SGCQ) and head and neck cancer patients quality of life scale (FACT-H\\&N). The research data will be statistically analyzed by SPSS 22.0 statistical software, and the statistical significance is defined as the P value less than 0.05 as the significant level. Statistical methods include 1) Descriptive statistics include times, percentages, averages, standard deviations, etc. 2) Inferential statistics: Chi-square test, independent t-test, paired t-test and Logistic regression were used to compare the post-test data between the experimental group and the control group, and to detect the effectiveness of intervention measures and 3) Using generalized estimating equations (GEE) to predict the effect of interventions (repeated measures) on OM severity, dry mouth, body weight, quality of life and comfort scores.\n\nExpected outcomes: This study aimed to investigate the efficacy of gargling with olive oil in reducing the incidence of OM, severity of OM, severity of dry mouth, severity of pain, and improved patient comfort and quality of life.",[25,26],"Oral Mucositis in Head and Neck Cancer","Chemo-radiotherapy",[28,29,26],"Oral Mucositis","Head and Neck Cancer","RECRUITING","2025-12-15",{"date":33,"type":34},"2025-12-18","ACTUAL",{"date":36,"type":34},"2022-12-04",{"date":38,"type":19},"2026-12",{"name":40,"class":41},"Chiayi Christian Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100528111","phase-3-evaluation-of-concomitant-chemo-radiotherapy-with-cisplatine-vs-gemcitabin-in-locally-advanced-cervicouterine-cancer-100528111","NCT06156514","Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer","Evaluation of Concomitant Chemo-radiotherapy With Cisplatin vs Gemcitabine as the First Line of Treatment in Patients With Locally Advanced Cervical Cancer, With Comorbidities and Preserved Renal Function, is a Phase III Clinical Trial.","MICHELE","Inclusion Criteria:\n\n* Singed informed consent.\n* Women with Age ≥ 18 years.\n\n  1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended.\n  2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion.\n* Previous bilateral oophorectomy\n* Age ≥ 60 years\n* Age \\\u003C60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters.\n* Diagnosis of CaCu EC IB2 mg\u002Fdl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso).\n* Patients who are candidates for treatment with concomitant QT \u002F RT.\n* ECOG 0-2.\n* Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1\n* No previous treatment.\n* Creatinine clearance ≥ 60 ml \u002F min calculated by the CKD-EPI formula.\n* Patients with adequate hematological and hepatic functioning, defined by the following parameters:\n\n  1. Hb equal to or greater than 10g \u002Fl. (Transfusion prior to treatment is allowed to reach this level of hemoglobin).\n  2. Leukocytes greater than or equal to 4000 \u002F mm3.\n  3. Platelets equal to or greater than 100,000mm3.\n  4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN\n* Patients with a prior diagnosis of the following comorbidities:\n\n  * Diabetes mellitus type 2, which has: fasting serum glucose \\\u003C250 mg\u002Fdl.\n  * Systemic arterial hypertension G1 or G2 according to CTCAE v4.03\n  * Child Pugh A liver disease\n  * Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction.\n  * Compensated heart failure in functional class I of the New York Heart Association.\n  * Systemic Lupus Erythematosus with mild or inactive lupus activity (less than or equal to 4 points according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).\n\nExclusion Criteria:\n\n* Patients with a second neoplasm.\n* Pregnant or lactating patients.\n* Patients with small cell and \u002F or neuroendocrine CaCu.\n* Patients with impaired renal function with a GFR \\\u003Cor equal to 60ml \u002F min calculated by the CKD-EPI formula\n* Patients with a history of active TB (TB)\n* Patients with a history of Human Immunodeficiency Virus (HIV) infection\n* Patients with vesico-vaginal or vesicorectal fistulas at diagnosis\n* Concomitant treatment with another experimental drug. Social, family or geographical conditions that suggest a poor attachment to the study\n\nCriteria Interruption of Treatment (Withdrawal of patients)\n\nA patient will be discontinued from the study under the following circumstances:\n\n* Evidence of disease progression.\n* If treating physician considers that a change of therapy may benefit the patient.\n* If patient withdrew consent\n* Due to unmanageable toxicity By pregnancy or if the patient does not wish to continue using the contraceptive methods indicated by the attending physician","FEMALE","18 Years",{"count":54,"type":19},140,[56],"PHASE3","The purpose of this phase III clinical trial, is to evaluate the efficacy and safety of concomitant chemo-radiotherapy with Cisplatin vs Gemcitabine as the first line of treatment in patients with locally advanced cervical cancer, with comorbidities and preserved renal function.",[59,60,26],"Locally Advanced Cervical Cancer","Gemcitabine",[62,63,60,64,65],"Locally advanced cervical cancer (LACC)","Concomitant chemo-radiotherapy","Cisplatin","Comorbidities","2025-05-22",{"date":68,"type":34},"2025-05-28",{"date":70,"type":34},"2019-11-06",{"date":72,"type":19},"2029-12-31",{"name":74,"class":75},"National Institute of Cancerología","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100472570","phase-2-a-two-blinded-multicentre-phase-iiiii-rct-of-concurrent-chemo-radiotherapy-combined-or-not-combined-with-tnf-as-the-therapy-for-la-npc-100472570","NCT05433597","A Two-blinded, Multicentre, Phase II\u002FIII RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC","A Two-blinded, Multicentre, Phase II\u002FIII RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for Local-advancedNPC","Inclusion Criteria:\n\n1. ≥18 years old and ≤60 years old;\n2. Pathologically confirmed nasopharyngeal carcinoma;\n3. Patients with primary locally advanced non-metastatic nasopharyngeal carcinoma who were eligible for standard concurrent radiotherapy and chemotherapy were in line with stage III and IVA defined by the International Union against Cancer and American Joint Commission on Cancer (UICC\u002FAJCC) staging System (version 8) (note: Stage III only included EBV-DNA\\>1×10\\^4 copy\u002FmL).\n4. Patients with locally advanced nasopharyngeal carcinoma who have not received prior radiotherapy or chemotherapy for the disease in this study;\n5. Karnofsky functional status score should be at least 70 points (the decline of functional status score caused by tumor should be appropriately relaxed after the judgment of the researcher, and the minimum score should be no less than 50 points. );\n6. At least 1 measurable lesion according to RECIST1.1 assessment criteria, measurable lesion should not have received local treatment such as radiotherapy;\n7. Expected survival ≥3 months;\n8. The function of vital organs meets the following requirements (not allowed within 14 days before screening . May use any blood components, cell growth factors, leukoplast, platelets Drugs, anemia correction drugs) :\n\n   * Neutrophil absolute count (ANC) ≥1.5×109\u002FL\n   * Platelet ≥100×109\u002FL;\n   * Hemoglobin ≥8.0g\u002F dL (note: Hemoglobin ≥8.0g\u002F dL can be achieved through blood transfusion or other intervention);\n   * Serum albumin ≥2.8g\u002FdL;\n   * Bilirubin ≤ 1.5x ULN, ALT and AST≤ 1.5x ULN; ALT and AST≤ 5x ULN if liver metastasis was present;\n   * creatinine clearance ≥50mL\u002Fmin\n9. Women of non-surgical sterilization or reproductive age and sexually active men enrolled in the study are required to use a medically effective form of contraception (such as an intrauterine device \\[IUD\\], birth control pills or condoms) for the duration of the study treatment and for at least 3 months after the last use of Tamfu and for at least 6 months after the last use of chemotherapy; The serum or urine HCG test of female patients of reproductive age who were not undergoing surgical sterilization must be negative within 7 days prior to study enrollment. And must be non lactation period; 10 Informed consent has been signed. -\n\nExclusion Criteria:\n\n1. Have a history of allergy to 5-FU, cisplatin and tumor necrosis factor;\n2. Previous treatment related to tumor necrosis factor (TNF);\n3. Major surgery other than nasopharyngeal cancer was diagnosed within 28 days prior to randomization or major surgery was expected during the study period;\n4. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); Subjects with vitiligo or asthma in complete remission during childhood without any intervention as adults could be included; Subjects with asthma requiring medical intervention with bronchodilators were excluded);\n5. Subject is taking immunosuppressants, or systemic, or absorbable sites Hormone therapy to achieve immunosuppression (dose \\>10mg\u002F day prednisone or Other equally effective hormones) and continued to be used within 2 weeks prior to enrollment.\n6. The subject has previous or co-existing malignancies (except those that have been cured and survived for more than 5 years without cancer, such as basal cell carcinoma of the skin, carcinoma in situ of the cervix and papillary carcinoma of the thyroid);\n7. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: ① HEART failure of NYHA grade 2 or above ② unstable angina pectoris ③ myocardial infarction within 1 year ⑤ clinically significant ventricular arrhythmias or ventricular arrhythmias requiring treatment or intervention;\n8. Subjects have active infection or have unexplained fever \\>38.5 degrees during screening but before the first dose (the investigator judged that the subjects' fever due to tumor could be included in the study);\n9. Subjects with congenital or acquired immune deficiency (e.g. HIV infected), or active hepatitis (reference: HBsAg, anti-HBS, HBeAg, anti-HBC, anti-HBE, HBV DNA≥10⁴\u002Fml, liver cell transaminase, etc.); Hepatitis C reference: HCV antibodies and HCVRNA);\n10. The subject has a known history of psychotropic drug abuse, alcoholism or drug abuse;\n11. In the judgment of the researcher, the subject has other factors that may lead to the termination of the study, such as other serious diseases (including mental diseases) requiring combined treatment, serious abnormal laboratory examination, family or social factors, which may affect the safety of the subject, or the collection of test data and samples.\n12. Women who are pregnant or breastfeeding, or who refuse\u002Fcannot accept medically acceptable conditions. For women with potential pregnancy and sexually active men.\n\n    \\-","60 Years",{"count":85,"type":19},172,[87,56],"PHASE2","Based on the application prospect of rmh-TNF combined with chemotherapy in the treatment of solid tumors. In this study, cisplatin combined with low dose 5-FU was proposed to enhance the immune function of 5-FU. Tianenfu is a novel recombinant modified human tumor necrosis with high activity and low toxicity. The fact that RMH-TNF has the potential of better in vivo efficacy and clinical antitumor effect. Therefore, the study was designed to investigate the treatment of concurrent chemoradiotherapy combined with TNF versus concurrent chemoradiotherapy combined with placebo for the efficacy and safety of advanced nasopharyngeal carcinoma.",[90,91,26],"Nasopharyngeal Carcinoma","TNF","NOT_YET_RECRUITING","2022-06-22",{"date":95,"type":34},"2022-06-27",{"date":97,"type":19},"2022-07-01",{"date":99,"type":19},"2029-07-01",{"name":101,"class":41},"Sun Yat-sen University"]